Chronic treatment with LY341495 decreases 5-HT2A receptor binding and hallucinogenic effects of LSD in mice

Neuroscience Letters

Volumn 536, Issue 1, 2013, Pages 69-73

  Moreno, José L ^a   Holloway, Terrell ^a   Rayannavar, Vinayak ^a   Sealfon, Stuart C ^a   González Maeso, Javier ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

G protein coupled receptor (GPCR); LY341495; Lysergic acid diethylamide (LSD); Metabotropic glutamate 2 (mGlu2) receptor; Schizophrenia; Serotonin 5 HT2A receptor

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR 2; KETANSERIN; LYSERGIDE; METABOTROPIC RECEPTOR 2; PROTEIN C FOS; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING ASSAY; BINDING SITE; CONTROLLED STUDY; HALLUCINATION; HEAD TWITCH; KNOCKOUT GENE; LIGAND BINDING; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DENSITY; SCHIZOPHRENIA; SOMATOSENSORY CORTEX;

AMINO ACIDS; ANIMALS; DRUG ANTAGONISM; EARLY GROWTH RESPONSE PROTEIN 1; EARLY GROWTH RESPONSE PROTEIN 2; HALLUCINOGENS; LYSERGIC ACID DIETHYLAMIDE; MALE; MICE; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-FOS; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, METABOTROPIC GLUTAMATE; SOMATOSENSORY CORTEX; STEREOTYPED BEHAVIOR; XANTHENES;

EID: 84873722486     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.12.053     Document Type: Article

References (27)

1. Ago Y., Yano K., Araki R., Hiramatsu N., Kita Y., Kawasaki T., Onoe H., Chaki S., Nakazato A., Hashimoto H., Baba A., Takuma K., Matsuda T. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology 2012, 65C:29.
2. Benneyworth M.A., Smith R.L., Sanders-Bush E. Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist. Neuropsychopharmacology 2008, 33:2206.
3. Benneyworth M.A., Xiang Z., Smith R.L., Garcia E.E., Conn P.J., Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Molecular Pharmacology 2007, 72:477.
4. Bespalov A.Y., van Gaalen M.M., Sukhotina I.A., Wicke K., Mezler M., Schoemaker H., Gross G. Behavioral characterization of the mGlu group II/III receptor antagonist LY-341495, in animal models of anxiety and depression. European Journal of Pharmacology 2008, 592:96.
5. Field J.R., Walker A.G., Conn P.J. Targeting glutamate synapses in schizophrenia. Trends in Molecular Medicine 2011, 12:689.
6. Fribourg M., Moreno J.L., Holloway T., Provasi D., Baki L., Mahajan R., Park G., Adney S.K., Hatcher C., Eltit J.M., Ruta J.D., Albizu L., Li Z., Umali A., Shim J., Fabiato A., Mackerell A.D., Brezina V., Sealfon S.C., Filizola M., Gonzalez-Maeso J., Logothetis D.E. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011, 147:1011.
7. Gewirtz J.C., Marek G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 2000, 23:569.
8. Geyer M.A., Vollenweider F.X. Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences 2008, 29:445.
9. Gonzalez-Maeso J. GPCR oligomers in pharmacology and signaling. Molecular Brain 2011, 4:20.
10. Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G., Gingrich J.A., Filizola M., Meana J.J., Sealfon S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452:93.
11. Gonzalez-Maeso J., Sealfon S.C. Agonist-trafficking and hallucinogens. Current Medicinal Chemistry 2009, 16:1017.
12. Gonzalez-Maeso J., Sealfon S.C. Psychedelics and schizophrenia. Trends in Neurosciences 2009, 32:225.
13. Gonzalez-Maeso J., Weisstaub N.V., Zhou M., Chan P., Ivic L., Ang R., Lira A., Bradley-Moore M., Ge Y., Zhou Q., Sealfon S.C., Gingrich J.A. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007, 53:439.
14. Jordan B.A., Trapaidze N., Gomes I., Nivarthi R., Devi L.A. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:343.
15. Koike H., Fukumoto K., Iijima M., Chaki S. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behavioural Brain Research 2012, 238C:48.
16. Kurita M., Holloway T., Garcia-Bea A., Kozlenkov A., Friedman A.K., Moreno J.L., Heshmati M., Golden S.A., Kennedy P.J., Takahashi N., Dietz D.M., Mocci G., Gabilondo A.M., Hanks J., Umali A., Callado L.F., Gallitano A.L., Neve R.L., Shen L., Buxbaum J.D., Han M.H., Nestler E.J., Meana J.J., Russo S.J., Gonzalez-Maeso J. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nature Neuroscience 2012, 15:1245.
17. Marek G.J., Wright R.A., Schoepp D.D., Monn J.A., Aghajanian G.K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. Journal of Pharmacology and Experimental Therapeutics 2000, 292:76.
18. 2A receptor agonists. Neuroscience Letters 2011, 493:76.
19. 2A-mGlu2 receptor heteromerization and its psychoactive behavioral function. Journal of Biological Chemistry 2012, 287:44301.
20. C. Muguruza, J.L. Moreno, A. Umali, L.F. Callado, J.J. Meana, J. Gonzalez-Maeso, Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects, European Neuropsychopharmacology, 2012, [Epub ahead of print].
21. Nichols D.E., Nichols C.D. Serotonin receptors. Chemical Reviews 2008, 108:1614.
22. Pfeiffer M., Koch T., Schroder H., Laugsch M., Hollt V., Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. Journal of Biological Chemistry 2002, 277:19762.
23. Quednow B.B., Kometer M., Geyer M.A., Vollenweider F.X. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 2012, 37:630.
24. Sorkin A., von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nature Reviews Molecular Cell Biology 2009, 10:609.
25. 2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006, 313:536.
26. Yokoi M., Kobayashi K., Manabe T., Takahashi T., Sakaguchi I., Katsuura G., Shigemoto R., Ohishi H., Nomura S., Nakamura K., Nakao K., Katsuki M., Nakanishi S. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science 1996, 273:645.
27. Zhai Y., George C.A., Zhai J., Nisenbaum E.S., Johnson M.P., Nisenbaum L.K. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 2003, 28:45.